Q. Serra-Camprubí

The BRD4S-LOXL2-MED1 interaction at the forefront of cell cycle transcriptional control in triple-negative breast cancer

Lorena Espinar, J. Arribas, L. Serrano, 2022, bioRxiv.

LOXL2‐mediated chromatin compaction is required to maintain the oncogenic properties of triple‐negative breast cancer cells

R. Dienstmann, V. Peg, L. Di Croce, 2024, The FEBS journal.

ESMO Scale for Clinical Actionability of Molecular Targets driving targeted treatment in patients with cholangiocarcinoma.

P. Nuciforo, R. Dienstmann, S. Aguilar, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple‐negative breast cancer

S. Sdelci, Anestis Gkanogiannis, Chiara Cannatá, 2023, EMBO molecular medicine.